Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free RDY Stock Alerts

Dr. Reddy's Laboratories (RDY) Financials

Dr. Reddy's Laboratories logo
$12.32 -0.83 (-6.28%)
As of 02:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Dr. Reddy's Laboratories

Annual Income Statements for Dr. Reddy's Laboratories

This table shows Dr. Reddy's Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 302 186 -129,548 272 0.00 0.00 23,568 0.00 0.00 671
Consolidated Net Income / (Loss)		 302 186 9,806 272 0.00 0.00 23,568 0.00 0.00 671
Net Income / (Loss) Continuing Operations		 302 186 -129,548 272 0.00 0.00 23,568 0.00 0.00 671
Total Pre-Tax Income 		410 226 -129,478 325 0.00 0.00 32,298 0.00 0.00 900
Total Operating Income		 447 208 -128,661 302 0.00 0.00 29,476 0.00 0.00 842
Total Gross Profit		 1,393 1,208 76,304 1,206 0.00 0.00 113,840 0.00 0.00 2,230
Total Revenue		 2,335 2,171 2,226 2,225 0.00 0.00 214,391 0.00 0.00 3,811
Operating Revenue		 2,335 2,171 2,226 2,225 0.00 0.00 214,391 0.00 0.00 3,811
Total Cost of Revenue		 942 963 65,724 1,018 0.00 0.00 100,551 0.00 0.00 1,581
Operating Cost of Revenue		 942 963 65,724 1,018 0.00 0.00 100,551 0.00 0.00 1,581
Total Operating Expenses		 946 1,000 65,163 904 0.00 0.00 84,364 0.00 0.00 1,388
Selling, General & Admin Expense		 690 715 46,857 704 0.00 0.00 62,081 0.00 0.00 1,099
Research & Development Expense		 269 301 18,265 226 0.00 0.00 17,482 0.00 0.00 320
Exploration Expense		 - - - 3.04 0.00 0.00 7,562 0.00 0.00 20
Other Operating Expenses / (Income)		 -13 -16 -12 -28 0.00 0.00 -2,761 0.00 0.00 -51
Total Other Income / (Expense), net		 -37 18 -817 22 0.00 0.00 2,822 0.00 0.00 58
Interest Expense		 75 12 - 17 0.00 0.00 958 0.00 0.00 33
Interest & Investment Income		 34 24 - 33 0.00 0.00 3,077 0.00 0.00 88
Other Income / (Expense), net		 3.46 5.38 -817 6.33 0.00 0.00 703 0.00 0.00 3.00
Income Tax Expense		 108 40 70 53 0.00 0.00 8,730 0.00 0.00 229
Basic Earnings per Share		 $117.34 $72.24 $59.13 $113.28 $117.63 $103.94 $142.08 $54.28 $66.93 $67.88
Weighted Average Basic Shares Outstanding		 170.55M - 165.91M 166.07M 166.17M 166.30M 166.43M 166.53M 166.82M 834.46M
Diluted Earnings per Share		 $116.98 $72.09 $0.91 $113.09 $117.40 $103.65 $141.69 $54.17 $66.80 $67.78
Weighted Average Diluted Shares Outstanding		 171.07M - 165.91M 166.07M 166.17M 166.30M 166.43M 166.53M 166.82M 834.46M
Weighted Average Basic & Diluted Shares Outstanding		 - - 165.91M 166.07M 166.17M 166.30M 166.43M 166.53M 166.82M 834.46M

Quarterly Income Statements for Dr. Reddy's Laboratories

No quarterly income statements for Dr. Reddy's Laboratories are available.

Annual Cash Flow Statements for Dr. Reddy's Laboratories

This table details how cash moves in and out of Dr. Reddy's Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Net Change in Cash & Equivalents		 58 -10 -1,294 -5.05 0.00 0.00 -701 0.00 0.00 85
Net Cash From Operating Activities		 623 -332 18,029 415 0.00 0.00 28,108 0.00 0.00 545
Net Cash From Continuing Operating Activities		 623 332 17,223 415 0.00 0.00 28,108 0.00 0.00 543
Net Income / (Loss) Continuing Operations		 302 186 9,806 272 0.00 0.00 23,568 0.00 0.00 671
Consolidated Net Income / (Loss)		 302 186 9,806 272 0.00 0.00 23,568 0.00 0.00 671
Depreciation Expense		 155 174 11,710 176 0.00 0.00 11,824 0.00 0.00 200
Non-Cash Adjustments To Reconcile Net Income		 274 143 1,784 10 0.00 0.00 18,651 0.00 0.00 256
Changes in Operating Assets and Liabilities, net		 -108 -171 -6,077 -43 0.00 0.00 -25,935 0.00 0.00 -584
Net Cash From Investing Activities		 -308 -285 -14,883 -112 0.00 0.00 -26,387 0.00 0.00 -682
Net Cash From Continuing Investing Activities		 -308 -285 -14,883 -112 0.00 0.00 -26,387 0.00 0.00 -682
Purchase of Property, Plant & Equipment		 -43 -632 -11,043 -121 0.00 0.00 -19,049 0.00 0.00 -403
Acquisitions		 -120 -0.26 - 0.00 0.00 0.00 -326 0.00 0.00 -622
Purchase of Investments		 -1,030 -767 -68,429 -1,136 0.00 0.00 -88,972 0.00 0.00 -2,983
Sale of Property, Plant & Equipment		 -180 0.68 139 31 0.00 0.00 3,316 0.00 0.00 15
Sale and/or Maturity of Investments		 1,065 1,114 64,450 1,114 0.00 0.00 78,644 0.00 0.00 3,311
Net Cash From Financing Activities		 -257 -57 -4,440 -308 0.00 0.00 -2,422 0.00 0.00 222
Net Cash From Continuing Financing Activities		 -257 -57 -4,440 -308 0.00 0.00 -1,971 0.00 0.00 168
Repayment of Debt		 -195 -4.67 -449 -243 0.00 0.00 2,175 0.00 0.00 246
Payment of Dividends		 -62 -52 -3,992 -58 0.00 0.00 -4,146 0.00 0.00 -78
Issuance of Debt		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Dr. Reddy's Laboratories

No quarterly cash flow statements for Dr. Reddy's Laboratories are available.

Annual Balance Sheets for Dr. Reddy's Laboratories

This table presents Dr. Reddy's Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Total Assets		 3,390 3,465 225,427 3,081 0.00 0.00 321,854 0.00 5,772
Total Current Assets		 1,548 1,684 114,501 1,729 0.00 0.00 204,253 0.00 2,928
Cash & Equivalents		 60 41 2,228 27 0.00 0.00 5,779 0.00 172
Short-Term Investments		 224 283 22,889 329 0.00 0.00 56,033 0.00 513
Accounts Receivable		 587 624 39,869 667 0.00 0.00 72,485 0.00 1,058
Inventories, net		 440 447 486 465 0.00 0.00 48,670 0.00 832
Other Current Assets		 185 220 12,536 183 0.00 0.00 20,069 0.00 353
Plant, Property, & Equipment, net		 881 889 54,088 694 0.00 0.00 66,462 0.00 1,144
Plant, Property & Equipment, gross		 881 889 54,088 694 0.00 0.00 66,462 0.00 1,144
Total Noncurrent Assets		 960 892 13,113 657 0.00 0.00 48,452 0.00 1,700
Long-Term Investments		 105 71 3,342 41 0.00 0.00 5,362 0.00 178
Goodwill		 58 61 3,902 53 0.00 0.00 4,245 0.00 138
Intangible Assets		 693 686 642 367 0.00 0.00 30,849 0.00 1,134
Noncurrent Deferred & Refundable Income Taxes		 86 56 4,168 162 0.00 0.00 7,196 0.00 238
Other Noncurrent Operating Assets		 18 18 1,059 34 0.00 0.00 800 0.00 12
Total Liabilities & Shareholders' Equity		 3,390 3,465 225,427 3,081 0.00 0.00 321,854 0.00 5,772
Total Liabilities		 1,477 1,523 85,230 1,025 0.00 0.00 90,863 0.00 1,825
Total Current Liabilities		 1,311 1,070 59,700 966 0.00 0.00 85,845 0.00 1,527
Short-Term Debt		 673 392 237 275 0.00 0.00 12,194 0.00 455
Accounts Payable		 207 247 14,613 221 0.00 0.00 26,444 0.00 489
Current Deferred & Payable Income Tax Liabilities		 23 23 181 7.60 0.00 0.00 2,144 0.00 35
Other Current Liabilities		 408 408 24,419 463 0.00 0.00 44,928 0.00 548
Total Noncurrent Liabilities		 166 452 25,530 59 0.00 0.00 5,018 0.00 298
Long-Term Debt		 84 385 318 17 0.00 0.00 1,278 0.00 92
Noncurrent Deferred & Payable Income Tax Liabilities		 19 11 610 3.65 0.00 0.00 833 0.00 165
Other Noncurrent Operating Liabilities		 63 56 42 38 0.00 0.00 2,907 0.00 41
Total Equity & Noncontrolling Interests		 1,913 1,942 140,197 2,056 0.00 0.00 230,991 0.00 3,947
Total Preferred & Common Equity		 1,913 1,942 139,379 2,056 0.00 0.00 230,611 0.00 3,903
Preferred Stock		 113 120 8,211 113 0.00 0.00 9,688 0.00 130
Total Common Equity		 1,799 1,823 131,168 1,943 0.00 0.00 220,923 0.00 3,773
Common Stock		 13 13 12 11 0.00 0.00 833 0.00 10
Retained Earnings		 1,666 1,749 128,646 1,913 0.00 0.00 215,593 0.00 3,697
Treasury Stock		 - 0.00 -535 -13 0.00 0.00 -1,269 0.00 -27
Other Equity Adjustments		 120 61 3,045 32 0.00 0.00 5,766 0.00 93
Noncontrolling Interest		 - - - - - - - 0.00 44

Quarterly Balance Sheets for Dr. Reddy's Laboratories

No quarterly balance sheets for Dr. Reddy's Laboratories are available.

Annual Metrics And Ratios for Dr. Reddy's Laboratories

This table displays calculated financial ratios and metrics derived from Dr. Reddy's Laboratories' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -7.02% 2.51% 1.98% -100.00% 0.00% 0.00% 14.69% 13.54% 0.00%
EBITDA Growth		 0.00% -35.99% -30,498.26% 31.63% -100.00% 0.00% 0.00% 67.01% 17.91% 0.00%
EBIT Growth		 0.00% -52.61% -60,738.78% 63.75% -100.00% 0.00% 0.00% 90.58% 18.02% 0.00%
NOPAT Growth		 0.00% -48.13% -52,764.97% 102.10% -100.00% 0.00% 0.00% 98.34% 23.01% 0.00%
Net Income Growth		 0.00% -38.55% 5,182.16% 80.44% -100.00% 0.00% 0.00% 91.22% 23.56% 0.00%
EPS Growth		 0.00% -38.37% -98.74% 91.68% 3.81% -11.71% 36.70% 91.16% 23.32% 1.47%
Operating Cash Flow Growth		 0.00% -153.28% 5,534.76% 49.89% -100.00% 0.00% 0.00% 109.46% -22.83% 0.00%
Free Cash Flow Firm Growth		 0.00% 0.00% -4,169.56% 396.27% -45.96% 787.05% 1,002.62% -708.40% 111.90% -101.73%
Invested Capital Growth		 0.00% 0.00% 1.89% -6.62% -10.13% -100.00% 0.00% 0.00% 21.27% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 59.65% 55.65% 3,428.09% 54.23% 0.00% 0.00% 53.10% 56.67% 58.61% 58.51%
EBITDA Margin		 25.92% 17.84% -5,290.93% 21.78% 0.00% 0.00% 19.59% 28.53% 29.63% 27.42%
Operating Margin		 19.15% 9.59% -5,780.31% 13.58% 0.00% 0.00% 13.75% 23.24% 24.26% 22.09%
EBIT Margin		 19.29% 9.83% -5,817.02% 13.86% 0.00% 0.00% 14.08% 23.39% 24.31% 22.17%
Profit (Net Income) Margin		 12.94% 8.55% 440.55% 12.22% 0.00% 0.00% 10.99% 18.33% 19.95% 17.61%
Tax Burden Percent		 73.74% 82.16% -7.57% 83.75% 0.00% 0.00% 72.97% 74.66% 77.48% 74.56%
Interest Burden Percent		 90.93% 105.82% 100.00% 105.24% 0.00% 0.00% 107.02% 104.96% 105.88% 106.51%
Effective Tax Rate		 26.26% 17.84% 0.00% 16.25% 0.00% 0.00% 27.03% 25.35% 22.52% 25.44%
Return on Invested Capital (ROIC)		 0.00% 14.99% -3,910.65% 11.25% 0.00% 0.00% 0.00% 49.17% 27.34% 34.58%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 22.93% 22,685.96% 18.42% 0.00% 0.00% 0.00% 40.80% 22.31% 7.21%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 4.42% 4,419.39% 2.44% 0.00% 0.00% 0.00% -10.15% -5.56% -0.58%
Return on Equity (ROE)		 0.00% 19.41% 508.74% 13.69% 0.00% 0.00% 0.00% 39.02% 21.77% 34.00%
Cash Return on Invested Capital (CROIC)		 0.00% -185.01% -3,912.52% 18.10% 10.67% 200.00% 0.00% -150.83% 8.11% -165.42%
Operating Return on Assets (OROA)		 0.00% 6.30% -3,777.82% 9.17% 0.00% 0.00% 0.00% 35.74% 19.14% 29.28%
Return on Assets (ROA)		 0.00% 5.48% 286.11% 8.08% 0.00% 0.00% 0.00% 28.00% 15.70% 23.25%
Return on Common Equity (ROCE)		 0.00% 18.26% 477.97% 12.87% 0.00% 0.00% 0.00% 37.32% 20.88% 32.50%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 9.71% 504.88% 13.41% 0.00% 0.00% 0.00% 19.54% 19.85% 17.19%
Net Operating Profit after Tax (NOPAT)		 330 171 -90,063 253 0.00 0.00 21,509 42,661 52,476 628
NOPAT Margin		 14.12% 7.88% -4,046.22% 11.37% 0.00% 0.00% 10.03% 17.35% 18.80% 16.47%
Net Nonoperating Expense Percent (NNEP)		 0.00% -7.94% -26,596.61% -7.16% 0.00% 0.00% 0.00% 8.37% 5.03% 27.37%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - 13.97%
Cost of Revenue to Revenue		 40.35% 44.35% 2,952.76% 45.77% 0.00% 0.00% 46.90% 43.33% 41.39% 41.49%
SG&A Expenses to Revenue		 29.54% 32.93% 2,105.13% 31.64% 0.00% 0.00% 28.96% 27.67% 27.65% 28.84%
R&D to Revenue		 11.53% 13.88% 820.59% 10.14% 0.00% 0.00% 8.15% 7.88% 8.19% 8.40%
Operating Expenses to Revenue		 40.50% 46.06% 2,927.55% 40.65% 0.00% 0.00% 39.35% 33.43% 34.34% 36.42%
Earnings before Interest and Taxes (EBIT)		 451 214 -129,478 308 0.00 0.00 30,179 57,514 67,876 845
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 605 387 -117,768 485 0.00 0.00 42,003 70,150 82,717 1,045
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 3.34 3.29 0.00 0.00 0.04 0.05 2.92
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 5.26 4.20 0.00 0.00 0.05 0.05 4.40
Price to Revenue (P/Rev)		 0.00 0.00 0.00 2.86 0.00 0.00 0.04 0.04 0.04 2.89
Price to Earnings (P/E)		 0.00 0.00 0.00 23.45 0.00 0.00 0.38 0.21 0.22 16.40
Dividend Yield		 1.44% 0.80% 1.02% 0.76% 0.73% 0.56% 1.25% 1.36% 1.33% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 4.26% 0.00% 0.00% 261.87% 482.82% 455.87% 6.10%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 3.06 3.28 0.00 0.00 0.00 0.00 2.99
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2.98 0.00 0.00 0.04 0.00 0.00 2.85
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 13.69 0.00 0.00 0.21 0.00 0.00 10.39
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 21.52 0.00 0.00 0.30 0.00 0.00 12.85
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 26.23 0.00 0.00 0.42 0.00 0.00 17.30
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 15.98 0.00 0.00 0.32 0.00 0.00 19.93
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 16.30 29.13 5.03 0.42 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.40 0.40 0.27 0.14 0.00 0.00 0.06 0.07 0.14
Long-Term Debt to Equity		 0.00 0.04 0.20 0.16 0.01 0.00 0.00 0.01 0.02 0.02
Financial Leverage		 0.00 0.19 0.19 0.13 0.01 -0.05 0.00 -0.25 -0.25 -0.08
Leverage Ratio		 0.00 1.77 1.78 1.69 1.55 1.50 0.00 1.39 1.39 1.46
Compound Leverage Factor		 0.00 1.88 1.78 1.78 0.00 0.00 0.00 1.46 1.47 1.56
Debt to Total Capital		 0.00% 28.36% 28.59% 21.49% 12.44% 0.00% 0.00% 5.51% 6.66% 12.17%
Short-Term Debt to Total Capital		 0.00% 25.21% 14.42% 9.17% 11.70% 0.00% 0.00% 4.99% 4.67% 10.12%
Long-Term Debt to Total Capital		 0.00% 3.15% 14.17% 12.32% 0.74% 0.00% 0.00% 0.52% 1.99% 2.05%
Preferred Equity to Total Capital		 0.00% 4.25% 4.40% 4.60% 4.80% 0.00% 0.00% 3.96% 3.58% 2.89%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.98%
Common Equity to Total Capital		 0.00% 67.39% 67.02% 73.91% 82.76% 0.00% 0.00% 90.37% 89.76% 83.96%
Debt to EBITDA		 0.00 1.95 -0.01 1.15 0.00 0.00 0.00 0.19 0.24 0.52
Net Debt to EBITDA		 0.00 0.95 0.00 0.30 0.00 0.00 0.00 -0.77 -0.81 -0.30
Long-Term Debt to EBITDA		 0.00 0.22 0.00 0.66 0.00 0.00 0.00 0.02 0.07 0.09
Debt to NOPAT		 0.00 4.43 -0.01 2.19 0.00 0.00 0.00 0.32 0.38 0.87
Net Debt to NOPAT		 0.00 2.15 0.00 0.57 0.00 0.00 0.00 -1.26 -1.27 -0.50
Long-Term Debt to NOPAT		 0.00 0.49 0.00 1.26 0.00 0.00 0.00 0.03 0.11 0.15
Altman Z-Score		 0.00 0.00 0.00 5.19 4.91 0.00 0.00 2.79 2.80 5.95
Noncontrolling Interest Sharing Ratio		 0.00% 5.93% 6.05% 6.01% 5.67% 5.48% 0.00% 4.36% 4.07% 4.41%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 1.18 1.57 1.92 1.79 0.00 0.00 2.38 2.58 1.92
Quick Ratio		 0.00 0.66 0.89 1.09 1.06 0.00 0.00 1.56 1.68 1.14
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -2,110 -90,106 407 220 1,951 21,509 -130,859 15,576 -3,003
Operating Cash Flow to CapEx		 278.87% -52.55% 165.34% 461.03% 0.00% 0.00% 178.66% 313.43% 172.42% 140.46%
Free Cash Flow to Firm to Interest Expense		 0.00 -175.24 0.00 24.20 0.00 0.00 22.45 -91.64 9.10 -91.01
Operating Cash Flow to Interest Expense		 8.32 -27.55 0.00 24.68 0.00 0.00 29.34 41.23 26.55 16.52
Operating Cash Flow Less CapEx to Interest Expense		 5.33 -79.97 0.00 19.33 0.00 0.00 12.92 28.07 11.15 4.76
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.64 0.65 0.66 0.00 0.00 0.00 1.53 0.79 1.32
Accounts Receivable Turnover		 0.00 3.70 3.68 3.71 0.00 0.00 0.00 0.00 3.65 0.00
Inventory Turnover		 0.00 2.19 148.25 2.18 0.00 0.00 0.00 0.00 2.06 0.00
Fixed Asset Turnover		 0.00 2.46 2.51 2.66 0.00 0.00 0.00 0.00 3.89 0.00
Accounts Payable Turnover		 0.00 4.65 289.90 4.46 0.00 0.00 0.00 0.00 4.03 0.00
Days Sales Outstanding (DSO)		 0.00 98.67 99.27 98.47 0.00 0.00 0.00 0.00 99.88 0.00
Days Inventory Outstanding (DIO)		 0.00 166.73 2.46 167.10 0.00 0.00 0.00 0.00 177.23 0.00
Days Payable Outstanding (DPO)		 0.00 78.41 1.26 81.90 0.00 0.00 0.00 0.00 90.59 0.00
Cash Conversion Cycle (CCC)		 0.00 186.99 100.48 183.67 0.00 0.00 0.00 0.00 186.52 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 2,281 2,325 2,171 1,951 0.00 0.00 173,520 210,420 3,631
Invested Capital Turnover		 0.00 1.90 0.97 0.99 0.00 0.00 0.00 2.83 1.45 2.10
Increase / (Decrease) in Invested Capital		 0.00 2,281 43 -154 -220 -1,951 0.00 173,520 36,900 3,631
Enterprise Value (EV)		 0.00 0.00 0.00 6,634 6,406 9,808 9,000 -34,680 -43,727 10,860
Market Capitalization		 0.00 0.00 0.00 6,372 6,398 9,808 9,000 9,334 12,215 11,002
Book Value per Share		 $0.00 $10.80 $10.99 $11.50 $11.70 $0.00 $0.00 $1,327.46 $1,620.06 $22.62
Tangible Book Value per Share		 $0.00 $6.29 $6.49 $7.30 $9.17 $0.00 $0.00 $1,116.59 $1,372.63 $14.99
Total Capital		 0.00 2,670 2,720 2,582 2,348 0.00 0.00 244,463 300,570 4,494
Total Debt		 0.00 757 777 555 292 0.00 0.00 13,472 20,020 547
Total Long-Term Debt		 0.00 84 385 318 17 0.00 0.00 1,278 5,990 92
Net Debt		 0.00 368 382 143 -105 0.00 0.00 -53,702 -66,707 -316
Capital Expenditures (CapEx)		 223 631 10,904 90 0.00 0.00 15,733 18,784 26,350 388
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 626 682 666 682 0.00 0.00 68,790 84,568 1,171
Debt-free Net Working Capital (DFNWC)		 0.00 910 1,006 1,029 1,038 0.00 0.00 130,602 166,040 1,856
Net Working Capital (NWC)		 0.00 237 614 792 763 0.00 0.00 118,408 152,010 1,401
Net Nonoperating Expense (NNE)		 28 -15 -99,869 -19 0.00 0.00 -2,059 -2,406 -3,208 -43
Net Nonoperating Obligations (NNO)		 0.00 369 382 143 -105 0.00 0.00 -57,471 -70,130 -316
Total Depreciation and Amortization (D&A)		 155 174 11,710 176 0.00 0.00 11,824 12,636 14,841 200
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 28.85% 30.64% 29.94% 0.00% 0.00% 0.00% 27.98% 30.29% 30.73%
Debt-free Net Working Capital to Revenue		 0.00% 41.92% 45.18% 46.27% 0.00% 0.00% 0.00% 53.12% 59.48% 48.70%
Net Working Capital to Revenue		 0.00% 10.92% 27.57% 35.62% 0.00% 0.00% 0.00% 48.16% 54.45% 36.76%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.91 $113.28 $117.63 $1.42 $142.08 $271.43 $334.65 $67.88
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 165.85M 166.07M 166.17M 166.30M 166.43M 166.53M 166.82M 834.46M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.91 $113.09 $1.56 $1.52 $141.69 $270.85 $334.02 $67.78
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 166.19M 166.07M 166.17M 166.30M 166.43M 166.53M 166.82M 834.46M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 165.91M 166.07M 166.17M 166.30M 166.43M 166.53M 166.82M 834.46M
Normalized Net Operating Profit after Tax (NOPAT)		 330 171 -90,026 253 0.00 0.00 21,509 42,661 52,476 628
Normalized NOPAT Margin		 14.12% 7.88% -4,044.55% 11.37% 0.00% 0.00% 10.03% 17.35% 18.80% 16.47%
Pre Tax Income Margin		 17.54% 10.41% -5,817.02% 14.59% 0.00% 0.00% 15.07% 24.55% 25.74% 23.62%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 6.02 17.73 0.00 18.34 0.00 0.00 31.50 40.28 39.67 25.61
NOPAT to Interest Expense		 4.40 14.20 0.00 15.04 0.00 0.00 22.45 29.87 30.67 19.02
EBIT Less CapEx to Interest Expense		 3.04 -34.69 0.00 12.98 0.00 0.00 15.08 27.12 24.27 13.85
NOPAT Less CapEx to Interest Expense		 1.42 -38.22 0.00 9.69 0.00 0.00 6.03 16.72 15.27 7.27
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 20.52% 28.16% 40.71% 21.29% 0.00% 0.00% 17.59% 11.05% 11.94% 11.62%
Augmented Payout Ratio		 20.52% 28.16% 40.71% 21.29% 0.00% 0.00% 17.59% 11.05% 11.94% 11.62%

Quarterly Metrics And Ratios for Dr. Reddy's Laboratories

No quarterly metrics and ratios for Dr. Reddy's Laboratories are available.


Financials Breakdown Chart

Dr. Reddy's Laboratories Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Dr. Reddy's Laboratories' fiscal year ends in March. Their fiscal year 2025 ended on March 31, 2025.

Dr. Reddy's Laboratories' net income appears to be on an upward trend, with a most recent value of $671 million in 2025, rising from $302.08 million in 2016. The previous period was $0.00 in 2024. Find out what analysts predict for Dr. Reddy's Laboratories in the coming months.

Dr. Reddy's Laboratories' total operating income in 2025 was $842 million, based on the following breakdown:
  • Total Gross Profit: $2.23 billion
  • Total Operating Expenses: $1.39 billion

Over the last 9 years, Dr. Reddy's Laboratories' total revenue changed from $2.34 billion in 2016 to $3.81 billion in 2025, a change of 63.2%.

Dr. Reddy's Laboratories' total liabilities were at $1.83 billion at the end of 2025, a 182,500,000,000.0% increase from 2024, and a 23.6% increase since 2017.

In the past 8 years, Dr. Reddy's Laboratories' cash and equivalents has ranged from $0.00 in 2021 to $5.78 billion in 2023, and is currently $172 million as of their latest financial filing in 2025.

Over the last 9 years, Dr. Reddy's Laboratories' book value per share changed from 0.00 in 2016 to 22.62 in 2025, a change of 2,261.7%.


Related Companies

Financial statements for NYSE:RDY last updated on 11/14/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for NV-387, its antiviral candidate targe...
Equiscreen | Sponsoredtc pixel
Rise of the… petroyuan?
On February 28th, Iran installed a yuan-denominated toll at the Strait of Hormuz - the chokepoint for one in e...
Golden Portfolio | Sponsoredtc pixel
BSEM: From OTC to Nasdaq Contender!
BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...
Huge Alerts | Sponsoredtc pixel
If You Have $50k+ on Coinbase, This Will Ruin Your Day
In 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank ac...
Decentralized Masters | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
Nevada gold explorer near Kinross district draws attention
Gold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...
Wall Street Logic | Sponsoredtc pixel